Novo Nordisk A/S (NVO) Gross Margin: 81.83%
Is Novo Nordisk A/S’s gross margin high or low?
Novo Nordisk A/S's gross margin of 81.83% is in line with its 5-year average of 83.48%, near the low end of its 5-year range (80.98%–84.67%).
As of Wednesday, June 17, 2026. 1.20% below its 12-month average of 82.83%.
NVO Gross Margin Chart
NVO Average Gross Margin Chart
NVO Current vs Average Gross Margin Chart
NVO Gross Margin Metrics
GROSS MARGIN
81.83%
GROSS MARGIN AVG TTM
82.83%
GROSS MARGIN AVG 3Y
83.54%
GROSS MARGIN AVG 5Y
83.48%
GROSS MARGIN AVG 10Y
83.86%
GROSS MARGIN AVG 15Y
83.71%
GROSS MARGIN AVG 20Y
82.51%
CURRENT VS TTM AVG
-1.20%
CURRENT VS 3Y AVG
-2.05%
CURRENT VS 5Y AVG
-1.98%
CURRENT VS 10Y AVG
-2.43%
CURRENT VS 15Y AVG
-2.25%
CURRENT VS 20Y AVG
-0.83%
NVO Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.39B | 81.83% | 82.83% | 83.54% | 83.48% |
| Amgen Inc. (AMGN)vs › | $184.40B | 71.46% | 66.16% | 69.53% | 71.51% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $171.57B | 39.41% | 39.50% | 40.36% | 43.54% |
| Gilead Sciences, Inc. (GILD)vs › | $155.75B | 79.35% | 78.55% | 78.10% | 78.28% |
| Abbott Laboratories (ABT)vs › | $154.08B | 56.38% | 53.17% | 51.86% | 51.92% |
| Pfizer Inc. (PFE)vs › | $147.73B | 69.35% | 68.05% | 62.23% | 63.06% |
| Intuitive Surgical, Inc. (ISRG)vs › | $142.44B | 66.29% | 66.73% | 66.82% | 67.04% |
| Danaher Corporation (DHR)vs › | $128.06B | 60.68% | 60.22% | 59.98% | 59.48% |
| CVS Health Corporation (CVS)vs › | $127.73B | 13.87% | 13.78% | 14.92% | 15.96% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $116.49B | 86.28% | 85.57% | 86.56% | 87.08% |
Gross Margin Analysis
Gross Margin
81.8%
(Revenue - COGS) / Revenue
Novo Nordisk A/S Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Gross Margin FAQ
- What is the gross margin for Novo Nordisk A/S (NVO)?
- The gross margin for NVO stock is 81.83%.
- Is Novo Nordisk A/S's gross margin high or low?
- Novo Nordisk A/S's gross margin of 81.83% is in line with its 5-year average of 83.48%, near the low end of its 5-year range (80.98%–84.67%).
- What is the TTM average gross margin for Novo Nordisk A/S (NVO)?
- The TTM average gross margin for NVO stock is 82.83%.
- What is the 3Y average gross margin for Novo Nordisk A/S (NVO)?
- The 3Y average gross margin for NVO stock is 83.54%.
- What is the 5Y average gross margin for Novo Nordisk A/S (NVO)?
- The 5Y average gross margin for NVO stock is 83.48%.
- What is the 10Y average gross margin for Novo Nordisk A/S (NVO)?
- The 10Y average gross margin for NVO stock is 83.86%.
- What is the 15Y average gross margin for Novo Nordisk A/S (NVO)?
- The 15Y average gross margin for NVO stock is 83.71%.
- What is the 20Y average gross margin for Novo Nordisk A/S (NVO)?
- The 20Y average gross margin for NVO stock is 82.51%.
Novo Nordisk A/S Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 80.98% |
| 2024-12-31 | 84.67% |
| 2023-12-31 | 84.60% |
| 2022-12-31 | 83.92% |
| 2021-12-31 | 83.20% |
| 2020-12-31 | 83.51% |
| 2019-12-31 | 83.54% |
| 2018-12-31 | 84.25% |
| 2017-12-31 | 84.21% |
| 2016-12-31 | 84.63% |
| 2015-12-31 | 85.00% |
| 2014-12-31 | 83.60% |
| 2013-12-31 | 83.08% |
| 2012-12-31 | 82.74% |
| 2011-12-31 | 81.03% |
| 2010-12-31 | 80.78% |
| 2009-12-31 | 79.56% |
| 2008-12-31 | 77.81% |
| 2007-12-31 | 76.60% |
| 2006-12-31 | 75.26% |
| 2005-12-31 | 72.81% |
| 2004-12-31 | 72.27% |
| 2003-12-31 | 71.96% |
| 2002-12-31 | 73.66% |
| 2001-12-31 | 74.85% |
| 2000-12-31 | 78.96% |
| 1999-12-31 | 77.92% |
| 1998-12-31 | 76.43% |
| 1997-12-31 | 72.20% |
| 1996-12-31 | 72.04% |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar